Last updated: October 26, 2026
Zinecard, the U.S. brand for dexrazoxane hydrochloride, is a mature oncology-support drug with limited standalone revenue visibility. Its commercial position is shaped by generic competition, narrow use in anthracycline-treated patients, hospital purchasing, and reduced utilization after changes in pediatric oncology practice. Pfizer remains associated with the U.S. product through its Hospira portfolio, but public filings do not disclose Zinecard-specific sales.
The financial trajectory is therefore best characterized as a low-growth, mature injectable market rather than a branded oncology growth asset. Market value is concentrated in institutional demand, supply reliability, regulatory compliance, and manufacturing access.
What is Zinecard and how is it used?
Zinecard is dexrazoxane hydrochloride for injection, administered intravenously to reduce the risk of doxorubicin-associated cardiomyopathy in selected patients. The drug is supplied as a powder requiring reconstitution before infusion.
The U.S. label identifies Zinecard for children and adults with cancer who have received cumulative doxorubicin doses that create a clinically meaningful cardiotoxicity risk. It is administered before doxorubicin, generally at a dexrazoxane-to-doxorubicin dose ratio of 10:1, subject to the approved labeling and treatment protocol. [1]
| Attribute |
Zinecard |
| Active ingredient |
Dexrazoxane hydrochloride |
| Dosage form |
Intravenous powder for injection |
| Primary use |
Reduction of doxorubicin-induced cardiomyopathy |
| Therapeutic area |
Oncology supportive care |
| Administration setting |
Hospital or oncology infusion center |
| U.S. brand owner association |
Pfizer, through the Hospira portfolio |
| Original U.S. approval |
1990s |
| Primary competitive threat |
Generic dexrazoxane injection |
| Orange Book status |
Product and patent status must be checked against the current FDA Orange Book; no durable blocking-patent position is evident from the mature product profile |
Zinecard is distinct from Totect, another dexrazoxane product approved for anthracycline extravasation. Totect has a different indication, dosing protocol, and commercial positioning. Confusing the two products can distort market-size and competitive analyses.
What is the FDA regulatory status of Zinecard?
Zinecard is an FDA-approved prescription oncology product. Its approval is based on dexrazoxane hydrochloride administered with doxorubicin for cardioprotection. FDA labeling contains warnings relating to myelosuppression, infection risk, embryo-fetal toxicity, and the need for appropriate dose administration. [1]
The product is not a biologic and does not face biosimilar competition. Any competing products are regulated through the abbreviated new drug application, or ANDA, pathway if they meet the requirements for generic equivalence.
How does Zinecard compare with Totect?
| Issue |
Zinecard |
Totect |
| Active ingredient |
Dexrazoxane hydrochloride |
Dexrazoxane hydrochloride |
| Core indication |
Prevention or reduction of anthracycline cardiotoxicity |
Treatment of anthracycline extravasation |
| Commercial setting |
Planned oncology treatment |
Acute administration after extravasation |
| Demand pattern |
Protocol-driven and recurring |
Episodic and emergency-driven |
| Main purchasing factor |
Oncology pathway inclusion and supply |
Emergency availability and hospital formulary access |
| Substitution analysis |
Cannot be treated as interchangeable solely because the active ingredient is the same |
Indication and dosing differ from Zinecard |
Zinecard demand depends on cumulative anthracycline exposure and institutional treatment protocols. Totect demand depends on the low-frequency occurrence of extravasation events and hospital stocking requirements.
When does Zinecard lose exclusivity?
Zinecard is a mature product and no longer depends on meaningful new-drug exclusivity. Its original regulatory exclusivity expired long ago. The relevant commercial question is patent and generic competition, not remaining new chemical entity protection.
| Exclusivity category |
Current commercial relevance |
| New chemical entity exclusivity |
Expired |
| Pediatric exclusivity |
No current barrier to generic entry |
| Orphan exclusivity |
Not the principal protection for the product |
| Formulation exclusivity |
No broadly recognized current barrier sufficient to preserve branded exclusivity |
| Method-of-use protection |
Any historical claims would face age, scope, and enforceability limits |
| Generic entry |
Legally available subject to ANDA approval and commercial supply |
Patent expiration is not equivalent to the date on which every commercial competitor enters. Generic launch depends on ANDA approval, manufacturing economics, procurement access, and the availability of an active marketing channel.
What patents protect Zinecard?
The commercial patent estate for Zinecard is unlikely to provide the protection associated with a newer oncology product. The active ingredient, dexrazoxane, has been known for decades, and the branded product has operated in a genericized market environment.
Relevant patent categories include:
- Composition patents covering dexrazoxane or related compounds.
- Formulation patents covering injectable presentations, reconstitution, or stability.
- Method-of-use patents covering cardioprotection during anthracycline therapy.
- Manufacturing patents covering synthesis, purification, or pharmaceutical-grade production.
The economic value of any surviving patent would depend on claim scope, expiration, Orange Book listing, and whether an ANDA filer could certify that the patent is invalid, unenforceable, or not infringed.
What formulations are protected by Zinecard patents?
Zinecard is an injectable lyophilized or powdered presentation that requires reconstitution. Potential formulation differentiation includes:
- Vial strength and concentration.
- Excipient composition.
- Stability after reconstitution.
- Container-closure system.
- Manufacturing controls for sterile production.
- Labeling and administration instructions.
For a mature injectable, manufacturing know-how and regulatory execution can be more important than a broad composition patent. A competitor that can produce a therapeutically equivalent product but cannot maintain sterile supply, stability, or consistent batch release has limited commercial value.
How many patents cover Zinecard?
A precise current count requires a live review of FDA Orange Book records, U.S. Patent and Trademark Office records, and the relevant product labels. The market does not appear to be controlled by a large, active patent thicket comparable to newer oncology drugs.
The practical IP position is likely:
| IP layer |
Commercial assessment |
| Active ingredient |
Weak protection because dexrazoxane is old |
| Core cardioprotection method |
Limited value from age and potential claim narrowness |
| Injectable formulation |
Possible technical value, but dependent on claim validity and listing |
| Manufacturing process |
More likely to create operational than litigation leverage |
| Trade secrets |
Potentially relevant to yield, impurity control, and sterile manufacture |
| Regulatory exclusivity |
Not a material current barrier |
What is the Orange Book status of Zinecard?
The FDA Orange Book is the controlling source for current approved products, therapeutic equivalence evaluations, and listed patents or exclusivity. For Zinecard, the key commercial questions are whether the brand is listed as actively marketed, whether an equivalent generic is approved, and whether any patents remain listed against the relevant NDA. [2]
An Orange Book listing does not by itself establish strong commercial protection. A listed patent may be old, narrow, vulnerable to an ANDA Paragraph IV challenge, or irrelevant to the generic's proposed label.
For investment and licensing purposes, the product should be classified as a mature injectable with potential supply and contracting risk, not as a protected branded asset.
Which companies are challenging Zinecard?
Competitive pressure comes primarily from generic dexrazoxane manufacturers rather than from a high-profile branded patent challenger. Generic companies can enter through ANDAs and may compete on hospital contracts, distributor access, and supply continuity.
Potential competitors include manufacturers with established sterile injectable businesses, including large generic and specialty-injectable suppliers. The competitive field can change when products are discontinued, placed on shortage lists, or removed from active marketing.
The most important competitor groups are:
- Generic dexrazoxane injection manufacturers.
- Contract manufacturers with sterile oncology capacity.
- Hospital purchasing organizations.
- Alternative cardiotoxicity-management protocols.
- Anthracycline-sparing or dose-limiting treatment regimens.
Publicly available information does not establish a current, high-value Paragraph IV litigation campaign directed at Zinecard comparable to the litigation surrounding major branded oncology products.
Are there Paragraph IV challenges to Zinecard?
A Paragraph IV certification is relevant only when an ANDA applicant addresses a listed patent by asserting that the patent is invalid, unenforceable, or not infringed. A current, commercially material Paragraph IV dispute involving Zinecard is not evident from the mature market profile and publicly available product information.
The absence of prominent litigation does not eliminate generic risk. It usually means one of three things:
- Relevant patents have expired.
- The product has few economically meaningful patents.
- Generic entrants can proceed without a dispute capable of supporting substantial damages or an injunction.
For Zinecard, generic entry risk is more likely to arise from routine ANDA competition than from a major patent settlement.
What patent litigation affects Zinecard?
No major active U.S. patent litigation is identified as a central driver of Zinecard's current market value. The commercial disputes most likely to affect the product would involve:
- ANDA approval and patent certifications.
- Product quality or manufacturing compliance.
- Contracting and supply interruptions.
- Trademark or brand-use disputes.
- Hospital purchasing exclusions.
- Regulatory action involving manufacturing sites.
This is materially different from newer oncology drugs, where patent litigation can delay generic entry for years and preserve billions of dollars in annual sales.
What generic entry risks exist for Zinecard?
Generic entry risk is high because the product is old, injectable, and clinically established. The market has several structural characteristics that favor generic substitution:
- No meaningful remaining new-drug exclusivity.
- A well-characterized active ingredient.
- Predictable hospital demand.
- Standardized administration.
- Limited consumer brand loyalty.
- Formulary and group-purchasing pressure.
- Existing generic-injectable manufacturing infrastructure.
Generic competition does not necessarily eliminate branded demand. Hospitals may retain the branded product when supply reliability, contracting, or physician familiarity offsets a price difference. That protection is commercial rather than legal and can disappear when a generic supplier offers lower pricing with dependable availability.
How strong is the patent estate for Zinecard?
Zinecard's patent estate is weak to moderate from an investment perspective. The active ingredient and therapeutic concept are old, while any residual protection is likely to depend on narrow formulation or manufacturing claims.
| Factor |
Assessment |
| Age of active ingredient |
Unfavorable for exclusivity |
| Generic substitution |
High risk |
| Patent blocking power |
Limited |
| Formulation differentiation |
Potentially relevant but narrow |
| Manufacturing complexity |
Moderate to high for sterile injectable production |
| Litigation leverage |
Low relative to newer oncology products |
| Regulatory moat |
Based on compliance and supply, not exclusivity |
| Brand premium |
Limited and institutionally negotiated |
The strongest defensible position would not be a broad molecule patent. It would be a combination of reliable sterile manufacturing, regulatory history, hospital contracts, and supply continuity.
What is the market size for dexrazoxane and Zinecard?
Public sources do not provide a reliable standalone U.S. revenue figure for Zinecard. Pfizer reports sales at broader business-segment levels and does not break out individual mature injectable products such as Zinecard. [3]
A top-down market estimate is difficult because claims data may combine:
- Zinecard.
- Generic dexrazoxane.
- Totect.
- Institutional purchases.
- Specialty distributors.
- Compounded or contract-supplied products.
- International products sold under different brand names.
The addressable market is constrained by the number of patients receiving cumulative doxorubicin exposure and by physician or institutional decisions on cardioprotection. It is therefore much smaller than the overall anthracycline market.
The commercial value of the market is driven by unit price and procurement share rather than by rapid volume growth. A branded supplier may retain revenue through price, supply reliability, or contracts even as total market value declines.
What is the financial trajectory for Zinecard?
Zinecard's likely financial trajectory has four stages:
| Period |
Financial pattern |
| Initial launch |
Premium pricing supported by branded status and limited competition |
| Genericization |
Price erosion and loss of exclusivity |
| Mature market |
Stable or declining volume with institutional procurement pressure |
| Supply-constrained phase |
Temporary pricing and share gains for reliable manufacturers |
The product is unlikely to be a material growth driver for Pfizer. Its financial importance is more likely to arise from portfolio economics, manufacturing utilization, and oncology-channel relationships.
Revenue exposure has three dimensions:
- Direct product sales.
- Margin contribution from a mature injectable.
- Strategic value of hospital and oncology distribution access.
Standalone sales estimates that are not supported by company disclosures should not be treated as verified financial data.
What licensing deals affect Zinecard?
No major recent licensing transaction is publicly established as a defining event in Zinecard's market trajectory. The product's economics are more likely to involve supply, distribution, or manufacturing arrangements than a large-value innovation license.
Relevant deal structures could include:
- Contract manufacturing.
- Regional commercialization rights.
- Hospital-group purchasing agreements.
- Distributor supply arrangements.
- Portfolio acquisitions involving sterile injectables.
- Licensing of formulation or manufacturing technology.
Any license valuation would depend on the remaining net price after generic competition, annual vial volume, manufacturing cost, regulatory obligations, and the probability of supply interruption.
How does Zinecard compare with newer oncology supportive-care drugs?
| Attribute |
Zinecard |
Newer oncology supportive-care product |
| Product age |
Mature |
Often recently launched |
| Patent protection |
Limited |
Potentially substantial |
| Pricing power |
Low to moderate |
Moderate to high if clinically differentiated |
| Buyer |
Hospital or oncology institution |
Hospital, payer, or specialty channel |
| Substitution |
Generic substitution likely |
May be restricted by patents or clinical differentiation |
| Revenue outlook |
Stable to declining |
Can grow rapidly after launch |
| Primary moat |
Manufacturing and supply |
Clinical data, patents, exclusivity, and reimbursement |
| Litigation exposure |
Low relative to new drugs |
Often high |
Zinecard's market is defensive only in the limited sense that it is tied to established oncology protocols. That demand is not equivalent to durable pricing power.
What manufacturing and IP barriers affect Zinecard?
Sterile injectable manufacturing is the most important operational barrier. A supplier must maintain:
- Validated aseptic processing.
- Sterility assurance.
- Consistent potency and impurity control.
- Reliable vial and packaging supply.
- FDA-compliant batch release.
- Adequate capacity for intermittent oncology demand.
- Stability data for the reconstituted product.
These barriers can reduce the number of reliable suppliers even when formal patent protection is weak. The result is a market in which shortages can temporarily increase the value of inventory, manufacturing capacity, or approved alternative suppliers.
The commercial risk is asymmetric. A single manufacturing problem can remove a supplier from the market, but an additional approved supplier can quickly pressure price.
What generic launch scenarios are most likely?
Base case
Generic suppliers maintain or expand share, while Zinecard remains available for institutions that prefer the branded product or have established contracts. Revenue gradually declines through price pressure and substitution.
Downside case
Multiple generic suppliers compete aggressively, producing substantial price erosion. The brand becomes a residual product with limited hospital demand.
Supply-disruption case
A generic manufacturing interruption creates temporary demand for the branded product. Pfizer or another reliable supplier captures short-term share, but the effect depends on inventory and manufacturing capacity.
Upside case
No durable volume-growth scenario is evident. The strongest upside would come from supply scarcity, a new contracting arrangement, or broader use of dexrazoxane in selected oncology protocols rather than from patent-driven pricing.
What is the competitive landscape for dexrazoxane?
The competitive landscape is determined by clinical protocol adoption, generic availability, and sterile manufacturing capacity.
Key competitors are not limited to named products. They include:
- Generic dexrazoxane injection.
- Totect for extravasation, in its separate indication.
- Alternative cardiotoxicity monitoring.
- Dose modification or anthracycline limitation.
- Liposomal doxorubicin and other treatment substitutions.
- Cardioprotective treatment strategies that do not use dexrazoxane.
Clinical guidelines and institutional protocols influence utilization. The American Society of Clinical Oncology and other oncology bodies generally frame dexrazoxane use around patient-specific cardiotoxicity risk rather than universal administration to every anthracycline-treated patient. [4]
Key Takeaways
- Zinecard is a mature dexrazoxane injectable used for anthracycline cardioprotection.
- Its original regulatory exclusivity has expired.
- Generic entry and hospital procurement are the main commercial forces.
- No major active patent litigation or Paragraph IV campaign is evident as a central market driver.
- The patent estate is weaker than that of newer oncology products.
- Sterile manufacturing, regulatory compliance, and supply reliability are more important than broad patent protection.
- Pfizer does not publicly disclose standalone Zinecard revenue.
- The financial trajectory is likely stable to declining, with temporary upside possible during supply disruptions.
- Zinecard and Totect should not be combined in market estimates because their indications and demand patterns differ.
- The product is not exposed to biosimilar competition because dexrazoxane is a small-molecule drug.
FAQs
Is Zinecard still commercially available?
Availability can vary by market, supplier, and time period. FDA product listings and current manufacturer information are the controlling sources for active marketing status. [2]
Is dexrazoxane a generic drug?
Yes. Dexrazoxane is an established small-molecule active ingredient, and generic dexrazoxane injection can compete through the ANDA pathway when FDA requirements are met.
Does Zinecard have a biosimilar?
No. Biosimilars apply to biologic products. Zinecard is a small-molecule injectable and is subject to generic-drug rules.
Is Zinecard used to treat doxorubicin extravasation?
Zinecard's principal labeling concerns anthracycline cardioprotection. Totect is the dexrazoxane product associated with anthracycline extravasation treatment. The products should not be treated as interchangeable without reviewing their labels and protocols.
What is the investment case for Zinecard?
The investment case is based on mature injectable cash flow, supply reliability, manufacturing access, and hospital contracting rather than patent-driven growth. Standalone revenue is not publicly reported, so valuation requires product-level commercial data that public filings do not provide.
References
- U.S. Food and Drug Administration. (n.d.). Zinecard (dexrazoxane hydrochloride) prescribing information. FDA.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
- Pfizer Inc. (2024). Annual report and Form 10-K. Pfizer.
- Armenian, S. H., Lacchetti, C., Barac, A., Carver, J., Constine, L. S., Denduluri, N., Dent, S., et al. (2017). Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. Journal of Clinical Oncology, 35(8), 893-911.
